Template:WikiDoc News: Today in Medicine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
''January 26, 2009 By Michael W Tempelhof, MD [mailto:tempe004@mc.duke.edu]''
'''January 26, 2009: Larry Husten, the former editor of TheHeart.Org, will serve as WikiDoc's first Director of Medical Journalism'''
*[[Image:lhusten.jpg|left]][http://cardiobrief.wordpress.com The exact nature and scope of the position have yet to be fully defined, but Husten said that he hopes to "encourage and facilitate the development of high quality medical journalism in this new medium." Husten was the editor of TheHeart.Org from its inception in 1999 until December 2008. Before that he was a freelance medical journalist who wrote for The Lancet, The New York Times, Discover, and a large number of other medical and computer publications. In 1994-1995 he was a Knight Science Journalism Fellow at MIT. He received a PHD in English from the State University of New York at Buffalo and drove a taxicab in New York City before embarking on a career in medical journalism. Larry's blog, www.cardiobrief.com, is a one-stop source for information about new and interesting events in the cardiology universe. The content will also appear on clinicaltrialresults.com and wikidoc.org]
 
'''January 26, 2009: FDA Announces Ongoing Safety Review of Clopidogrel'''
*[http://cardiobrief.wordpress.com/2009/01/26/fda-announces-ongoing-safety-review-of-clopidogrel In an “early communication” posted on its website, the FDA announced today that it was examining the safety of clopidogrel.  The review is a response to recent studies showing widespread variability in the efficacy of clopidogrel,  based on genetic differences in the metabolism of the drug, or when it is administered with other drugs, such as PPIs.  Eric Topol told CardioBrief that “pending work that needs to be done,” he believes that “genotyping for CYP2C19 will be indicated if it is shown that increasing the dose of clopidogrel overrides the lack of anti-platelet action.” He was more skeptical about the PPI story, noting that “the same scare with some statins proved a non-issue,” but agreed that the issue required further study.  The FDA told Dow Jones  that it was working with Bristol-Myers to update the drug’s label and that it was in discussions with Bristol-Myers and its partner on the drug, Sanofi-Aventis, about new clinical trials concerning this issue. (CardioBrief]
 
'''January 26, 2009: Danish Researchers Recommend Avoiding NSAIDs in HF'''
*[http://cardiobrief.wordpress.com/2009/01/26/danish-researchers-recommend-avoiding-nsaids-in-hf NSAIDs are associated with significant increases in death and cardiovascular morbidity, according to a large, new registry study from Denmark in the Archives of Internal Medicine. Danish researchers found dose-dependent elevated risk levels for death and risk of hospitalization with use of rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs. They conclude that “patients with HF should, if possible, avoid using any NSAIDs at any dosage for most NSAIDS and at high dosages for ibuprofen and naproxen.”  Dr. Steven Nissen agrees with the recommendation of the researchers but fully acknowledges the limitations of this type of research. He told CardioBrief:  “Like all observational studies, this one has important weaknesses. There are many known and unknown confounders for which adjustment is not possible. All NSAIDs increase sodium retention and these drugs have long been associated with increased risk of heart failure. With regard to the effects on MI and mortality, the results suggest a class effect, but this can only be verified by a well-designed, prospective randomized trial. We are conducting such as study, the PRECISION trial in 20,000 patients using three of these drugs, naproxen, ibuprofen, and celecoxib. Until the results are available, prudent practitioners should use NSAIDs in high risk patients only when absolutely necessary and should always use the lowest effective dosage for the least duration possible.”(CardioBrief)]
 
'''January 26, 2009: Innovative stent company seeks emergency intervention'''
*[http://cardiobrief.wordpress.com/2009/01/26/innovative-stent-company-seeks-emergency-intervention/ Xtent, a small company developing an innovative drug-eluting stent system featuring customized lengths and diameters, is being seriously threatened by the financial crisis. The company has announced that it will fire 112 of its 121 employees unless it can strike some sort of deal. Click to see the press release.(CardioBrief)]
 
'''January 26, 2009: Evidence-Based Treatment for HF Sees Improvements'''
*[http://www.bmj.com/cgi/content/short/338/jan26_2/b36?q=rss_home Australian researchers have seen long-term improvement in heart attack patients undergoing evidence-based treatments.  The study, printed in the British Medical Journal, did a 12-year follow-up on 4,500 Australians who survived 28 days after a myocardial infarction.  The researchers noted improving trends for those treated with a progressive regime of evidence-based treatments and coronary revascularization in their initial admission to the hospital and over the following year.  (British Medical Journal)]
 
'''January 26, 2009: Follow-Up: Surgeons Adopting Strict Rules on Payments'''
*[http://online.wsj.com/article/SB123275818015611957.html?mod=loomia&loomia_si=t0:a16:g2:r2:c0.130796:b0 The North American Spine Society now requires its members to disclose all ties to medical device companies - including dollar amounts.  Two weeks ago we told you about a University of Wisconsin researcher who raked in more than $19 million over five years from spinal device maker Medtronic.  After coming under fire from lawmakers, the NASS made its disclosure policy dramatically stricter.  The Wisconsin researcher had only been required to report earning "more than $20,000" in donations from medical companies.  (Wall Street Journal)]
 
'''January 26, 2009 By Michael W Tempelhof, MD [mailto:tempe004@mc.duke.edu]'''


'''Measuring Fractional Flow Reserve During PCI Improves 1-Year Outcomes.'''
'''Measuring Fractional Flow Reserve During PCI Improves 1-Year Outcomes.'''
Line 25: Line 43:


==Source==
==Source==
http://N Engl J Med. 2009 Jan 15;360(3):213-24.
N Engl J Med. 2009 Jan 15;360(3):213-24.


[[category:news]]
[[category:news]]
[[Category: Cardiovascular interventions News]]
[[Category: Cardiovascular interventions News]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


'''January 23, 2009: Citing Costs, Younger Americans Skipping Meds'''
'''January 23, 2009: Citing Costs, Younger Americans Skipping Meds'''

Revision as of 21:57, 26 January 2009

January 26, 2009: Larry Husten, the former editor of TheHeart.Org, will serve as WikiDoc's first Director of Medical Journalism

January 26, 2009: FDA Announces Ongoing Safety Review of Clopidogrel

January 26, 2009: Danish Researchers Recommend Avoiding NSAIDs in HF

January 26, 2009: Innovative stent company seeks emergency intervention

January 26, 2009: Evidence-Based Treatment for HF Sees Improvements

January 26, 2009: Follow-Up: Surgeons Adopting Strict Rules on Payments

January 26, 2009 By Michael W Tempelhof, MD [1]

Measuring Fractional Flow Reserve During PCI Improves 1-Year Outcomes.

Percutaneous coronary intervention (PCI) for treatment of NSTEMI and/or STEMI from ischemia has been associated with improvements in short-term and long-term clinical outcomes. However, in ischemic patients with multiple vessel disease, determination of which lesion is the culprit stentoic lesion requiring intervention is often difficult. -Fractional Flow Reserve (FFR): is the ratio of maximal blood flow in a stenotic vessel to normal maximal flow.

STUDY OBJECTIVE: To investigate whether FFR-guided PCI would be associated with better outcomes (rates of major adverse cardiac events (MACE) at 1 year, death, MI, or repeat revascularization at 1 year) vs. routine angiography-guided PCI in ischemic patients with multivessel disease.

STUDY DESIGN and METHODS: 1005 Patients with stenoses of >50% in at least two of the three major coronary arteries where randomized to either routine PCI, or FFR-guided PCI, where FFR was measured in all significant stenoses, with stenting in lesions with an FFR ≤0.8.

RESULTS: Rates of MACE at 1 year was significantly lower in the FFR arm compared with the routine-PCI arm (13.2% vs. 18.3%, p = 0.02). The incidence of death (1.8% vs. 3.0%, p = 0.19), myocardial infarction (MI) (5.7% vs. 8.7%, p = 0.07), and coronary artery bypass grafting or revascularization at year (6.5% vs. 9.5%, p = 0.08) was similar between both arms.

Mean procedure time was similar between the two study arms 70 minutes. Quantity of contrast dye utilized was significantly lower in the FFR arm, 272ml vs. 302 ml for standard PCI arm. The number of patients who were angina free at 1 year was also similar between the two arms (81% vs. 78%, p = 0.2). As measured by the EuroQOL-5D, the quality of life scores were similar between the two arms(p = 0.65).

CONCLUSIONS: The FAME trial results indicate that FFR-guided PCI is associated with a significantly lower incidence of MACE at year compared with routine angiography-guided PCI in ischemic patients with multivessel disease. FFR-guided PCI had a favorable cost-benefit ratio, similar procedural times to standard PCI and exposed patients to less contrast dye.

Tonino PA, De Bruyne B, Pijls NH, et al., on behalf of the FAME Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.

Source

N Engl J Med. 2009 Jan 15;360(3):213-24.

January 23, 2009: Citing Costs, Younger Americans Skipping Meds

January 23, 2009: Women with Heart Problems Often Left Waiting

January 23, 2009: 4,000-Person Drug Trial Scrapped After Sponsor Declares Bankruptcy

January 23, 2009: MA State Ethics Law Scuttles Plans for Medical Meeting

January 22, 2009: Gifts to Doctors Must Be Disclosed

January 22, 2009: Stroke Survivors with AF Have Greater Risk of Death

January 22, 2009: Women Make Better Heart Care Doctors?

January 22, 2009: American Journal of Clinical Nutrition

January 21, 2009: Pictures of a Bleeding Heart

January 21, 2009: More Doctors E-Mailing It In

January 21, 2009: Problems Pumping Iron? Maybe You’ve Got a Problem Pumping Blood

January 21, 2009: Bill Gates, Others Pledge $630 Million to End Polio

January 20, 2009: With a New President, a New Worry

January 20, 2009: First Time Heart Attacks Not as Severe

January 20, 2009: The “Sure Thing” Gene

January 20, 2009: Men Better at Resisting Temptation

January 20, 2009: Drug-Resistant Staph Infections Rising in Kids

January 16, 2009: Brian Blank has joined WikiDoc as its inaugural Scholar in Medical Journalism

January 16, 2009: Popular Health Risk Tools Don’t Find Heart Disease

January 16, 2009: Heparin-Induced Antibodies Point To Thrombosis Risk

January 16, 2009: Superbugs Vs. Cancer Drugs

January 16, 2009: Senator: Schools Failing to Regulate Medical Conflicts of Interest

January 16, 2009: Coffee Can Reduce Alzheimer’s, Cause Hallucinations

January 6, 2009: Cytochrome P450 2C19 polymorphism linked to poor outcomes for young MI patients treated with clopidogrel



More News: Click on one of the links below for more news

All News Articles

Acute Coronary Syndromes | Biomarker | Cardiovascular Imaging | CT Surgery | Diabetes | Electrophysiology | General Cardiology | Guidelines | Health Policy | Heart Failure | Hypertension | Interventional | Peripheral Arterial Disease | Prevention | Valvular Heart Disease |